iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

This first-in-human trial is testing tiny biological particles called exosomes (naturally released by cells and loaded with a gene-silencing molecule) to treat metastatic pancreatic cancer in patients whose tumors have a specific mutation called KrasG12D — one of the most common mutations found in pancreatic cancer. **You may be eligible if...** - You have metastatic pancreatic cancer confirmed by biopsy - Your tumor has been tested and found to have the KrasG12D mutation (from blood or tissue testing) - You have already received at least one prior treatment for your cancer, and your disease has either progressed or been stable for at least 4 months - You are in reasonably good physical health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - Your tumor does not have the KrasG12D mutation - You have not yet received any prior systemic treatment - Your overall health is too poor to tolerate treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.